[1] Ripley TL, Nutescu E. Anticoagulation in patients with heart failure and normal sinus rhythm[J].Am J Health Syst Pharm,2009,66(2):134-141. [2] Nair A, Sealove B, Halperin JL, et al. Anticoagulation in patients with heart failure: who, when, and why[J] ? Eur Heart J,2006(Supplenent E),8:E32-E38. [3] Altinisik J,Ates O, Ulutin T,et al. Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients[J]. Clin Appl Thromb Hemost, 2008,14(4):415-420. [4] 朱广瑾,王凌燕,段岩平,等.大鼠心肌缺血及再灌时血浆蛋白C的变化[J].基础医学与临床,1994,14(5):372-374. [5] Raivio P, Fernández JA, Kuitunen A,et al. Activation of protein C and hemodynamic recovery after coronary artery bypass surgery[J]. J Thorac Cardiovasc Surg, 2007,133(1):44-51. [6] Toulon P, Smirnov M, Triscott M, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study [J]. Thromb Res, 2009,124(1):137-143. [7] 张根葆,陈冬云,周志泳,等.蝮蛇毒蛋白C激活物的纯化与抗血小板活性[J].皖南医学院学报,2005,24(1):8-10. [8] Mahmoodi BK,Brouwer JP, Veeger N, et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. [J].Circulation,2008,118(16): 1659-1667. [9] Loubele STB,Spek CA, Leenders A,et al. Activated protein C protects against myocardial ischemia/ reperfusion injury via inhibition of apoptosis and inflammation [J]. Arterioscler Thromb Vasc Biol, 2009,29(7):1087-1092. [10] 王宗奎,林方昭,肖小璞,等.蛋白C、蛋白S的研究与应用[J].中国输血杂志,2010, 23(14):322-325. |